Shield raises €8.2m series A from Inventages to fund Phase III trial
This article was originally published in Scrip
Executive Summary
Privately-held Shield Therapeutics has raised €8.2 million from Inventages Venture Capital in its first series A institutional financing round - money that will help the company progress its lead compound, ST10-021, into Phase III trials and subsequently to a filing.